The prostaglandin e 2 receptor EP 2 is required for cyclooxygenase 2-mediated mammary hyperplasia

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4496-4499

  Chang, Sung Hee ^a   Ai, Youxi ^a   Breyer, Richard M ^b   Lane, Timothy F ^c   Hla, Timothy ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; CAY 10399; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; G PROTEIN COUPLED RECEPTOR; ICOSANOID; MESSENGER RNA; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; GLYCOPROTEIN; PROSTAGLANDIN EP2 RECEPTOR; PROSTAGLANDIN SYNTHASE; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST DEVELOPMENT; BREAST HYPERPLASIA; BREAST TUMOR; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; MALE; MAMMARY GLAND; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; MULTIPARA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; HYPERPLASIA; INBREEDING; PATHOLOGY; PHYSIOLOGY; PREGNANCY; UDDER;

ANIMALS; CYCLOOXYGENASE 2; FEMALE; GLYCOPROTEINS; HYPERPLASIA; INBREEDING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PREGNANCY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, PROSTAGLANDIN E; SIGNAL TRANSDUCTION;

EID: 19644379770     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0129     Document Type: Article

References (19)

1. Dannenberg AJ, Subbaramaiah K. Targeting cydooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6.
2. Couzin J. Clinical trials. Nail-biting time for trials of COX-2 drugs. Science 2004;306:1673-5.
3. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
4. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-9.
5. Chang SH, Liu CH, Conway R, et al. Rote of prostaglandin E2-dependent angiogenic switch in cyclo-oxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004;101:591-6.
6. Kennedy CR, Zhang Y, Brandon S, et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 1999;5:217-20.
7. Sanchez T, Estrada-Hernandez T, Paik JH, et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003;278:47281-90.
8. Normanno N, Ciardiello F. EGF-related peptides in the pathophysiology of the mammary gland. J Mammary Gland Biol Neoplasia 1997;2:143-51.
9. Luetteke NC, Qiu TH. Fenton SE, et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999;126:2739-50.
10. Chang S. Liu CH, Wu MT, Hla T. Regulation of vascular endothelial growth factor expression in mouse mammary tumor cells by the EP2 subtype of prostaglandin E2 receptor. Prostaglandins Other Lipid Mediat. In press 2005.
11. Shao J, Evers BM. Sheng H. Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J Biol Chem 2004;279:14287-93.
12. Wang D, Wang H. Shi Q, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor 8. Cancer Cell 2004;6:285-95.
13. Mutoh M. Watanabe K, Kitamura T. et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002;62:28-32.
14. Seno H, Oshima M, Ishikawa TO, et al. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Δ716) mouse intestinal polyps. Cancer Res 2002;62:506-11.
15. Sheng H. Shao J, Washington MK. DuBois RM. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276: 18075-81.
16. Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 2004;3:1031-9.
17. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
18. Howe LR, Subbaramaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002;62:5405-7.
19. Kenney NJ, Smith GH, Rosenberg K, Cutler ML, Dickson RB. Induction of ductal morphogenesis and lobular hyperplasia by amphiregulin in the mouse mammary gland. Cell Growth Differ 1996;7:1769-81.